Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.0 million.

  • Tonix Pharmaceuticals Holding's Change in Account Payables rose 11606.1% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 22013.93%. This contributed to the annual value of $927000.0 for FY2024, which is 12656.16% up from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Change in Account Payables of $1.0 million as of Q3 2025, which was up 11606.1% from $3.1 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Change in Account Payables ranged from a high of $3.7 million in Q2 2024 and a low of -$6.4 million during Q3 2024
  • Moreover, its 3-year median value for Change in Account Payables was $581000.0 (2024), whereas its average is $106272.7.
  • Data for Tonix Pharmaceuticals Holding's Change in Account Payables shows a peak YoY increase of 42521.82% (in 2024) and a maximum YoY decrease of 72507.37% (in 2024) over the last 5 years.
  • Tonix Pharmaceuticals Holding's Change in Account Payables (Quarter) stood at -$3.9 million in 2023, then soared by 114.76% to $581000.0 in 2024, then soared by 75.73% to $1.0 million in 2025.
  • Its Change in Account Payables stands at $1.0 million for Q3 2025, versus $3.1 million for Q2 2025 and -$353000.0 for Q1 2025.